Pharmaceutical Control of the
Human Microbiome

U.S. Patent and Trademark Office Issues Notice of Allowance of Patent Licensed to Symberix

March 2016

Symberix and licensor, University of North Carolina at Chapel Hill, received a Notice of Allowance from the U.S. Patent and Trademark Office for a pharmaceutical patent application related to using non-antibiotic, small molecules to address side effects from chemotherapeutic drugs. The patent application is titled “Selective Beta-Glucuronidase Inhibitors as a Treatment for Side Effects of Camptothecin Antineoplastic Agents".



Back to News